{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:08Z","timestamp":1789824728241,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is an ultra\u2010rare pediatric neurodegenerative disorder characterized by deficiency of the lysosomal enzyme tripeptidyl peptidase\u20101 (TPP1). In the absence of adequate TPP1, lysosomal storage material accumulation occurs in the central nervous system (CNS) accompanied by neurodegeneration and neurological decline that culminates in childhood death. Cerliponase alfa is a recombinant human TPP1 enzyme replacement therapy administered via intracerebroventricular infusion and approved for the treatment of CLN2 disease. Here, we describe two allometric methods, calculated by scaling brain mass across species, that informed the human dose selection and exposure prediction of cerliponase alfa from preclinical studies in monkeys and a dog model of CLN2 disease: (1) scaling of dose using a human\u2010equivalent dose factor; and (2) scaling of compartmental pharmacokinetic (PK) model parameters. Source PK data were obtained from cerebrospinal fluid (CSF) samples from dogs and monkeys, and the human exposure predictions were confirmed with CSF data from the first\u2010in\u2010human clinical study. Nonclinical and clinical data were analyzed using noncompartmental analysis and nonlinear mixed\u2010effect modeling approaches. Both allometric methods produced CSF exposure predictions within twofold of the observed exposure parameters maximum plasma concentration (C<jats:sub>max<\/jats:sub>) and area under the curve (AUC). Furthermore, cross\u2010species qualification produced consistent and reasonable PK profile predictions, which supported the allometric scaling of model parameters. The challenges faced in orphan drug development place an increased importance on, and opportunity for, data translation from research and nonclinical development. Our approach to dose translation and human exposure prediction for cerliponase alfa may be applicable to other CNS administered therapies being developed.<\/jats:p>","DOI":"10.1111\/cts.13028","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T16:42:47Z","timestamp":1622652167000},"page":"1810-1821","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease"],"prefix":"10.1111","volume":"14","author":[{"given":"Kevin","family":"Hammon","sequence":"first","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"de Hart","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Vuillemenot","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Kennedy","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Musson","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin L.","family":"Katz","sequence":"additional","affiliation":[{"name":"Mason Eye Institute University of Missouri School of Medicine Columbia Missouri USA"},{"name":"Department of Bioengineering University of Missouri Columbia Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Henshaw","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc. Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2009022"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10074"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199590018.003.0007"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.8.1676"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199590018.003.0023"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30368-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712649"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.09.004"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23423"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2014.06.008"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2014.03.005"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/6.4.551"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781139167826"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-7429.2007.00272.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12925"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.03.004"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058099"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.01.014"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.02.016"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3570049"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-199707000-00001"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw072"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7311"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2016.10.022"},{"key":"e_1_2_9_26_1","unstructured":"US Food and Drug Administration (FDA).Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July2005.https:\/\/www.fda.gov\/media\/72309\/download. Accessed January 6 2020."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70061-9"},{"key":"e_1_2_9_28_1","unstructured":"BarbierA McCauleyT RichardCWIII.Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate\u20102\u2010sulfatase. US9682129B2 United States Patent and Trademark Office June 20 2017."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.06.018"},{"issue":"10","key":"e_1_2_9_30_1","first-page":"S12","article-title":"Development changes in pharmacokinetics and pharmacodynamics","volume":"58","author":"Van den Anker J","year":"2018","journal-title":"J Clin Pharm"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/10837450902891360"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-019-09641-8"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:57:58Z","timestamp":1692953878000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/cts.13028"],"URL":"https:\/\/doi.org\/10.1111\/cts.13028","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"2020-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}